公开(公告)号：US20230126241A1

公开(公告)日：2023-04-27

申请号：US17914700

申请日：2021-02-03

Applicant: Agilent Technologies, Inc.

Inventor： Jinchun Wang ,  Jurgen Del Favero ,  Weidong Wu ,  Holly Hogrefe

IPC: C12Q1/686 ,  C12Q1/6876

Abstract: Methods and compositions are described for multi-stage primer extension reactions such as multiplex polymerase chain reactions (PCR) and reverse transcriptase PCR. Primer extension stages are performed in a closed vessel without opening the vessel between stages. The multi-stage primer extension methods and compositions utilize earlier stage primers in an earlier stage and later stage primers in a later stage, wherein the later stage primers are blocked from extension during the earlier stage. The blocked primers of the present technology comprise photocleavable blocking groups and are substantially inactive until the blocking group is cleaved by exposure to ultraviolet light. The blocked primers can be activated by ultraviolet light without opening the vessel.

公开(公告)号：US11926870B2

公开(公告)日：2024-03-12

申请号：US17172540

申请日：2021-02-10

Applicant: Agilent Technologies, Inc.

Inventor： Jurgen Del Favero

IPC: C12Q1/68 ,  C12Q1/6818 ,  C12Q1/6851 ,  C12Q1/6853 ,  C12Q1/686

CPC classification number: C12Q1/686 ,  C12Q1/6818 ,  C12Q1/6851 ,  C12Q1/6853 ,  C12Q2525/131 ,  C12Q2525/301 ,  C12Q2537/143 ,  C12Q2561/113 ,  C12Q2565/101

Abstract: The present invention relates to the technical field of nucleic acid amplification using a Polymerase Chain Reaction (PCR). Specifically, the present invention relates to Polymerase Chain Reaction (PCR) primers and Polymerase Chain Reaction (PCR) nucleic acid amplification mixture and the use thereof in (quantitative) Polymerase Chain Reactions (PCR). Specifically, the present invention relates to Polymerase Chain Reaction (PCR) primers suitable for use in Restriction Mediated quantitative PCR (RM-qPCR) nucleic acid amplification reactions comprising a 5′ Acceptor representing one member of a fluorescence resonance energy transfer (FRET) pair; A representing a nucleic acid sequence motif of 10 to 30 bp; 3-C representing a linker region comprised of at least three carbon atoms; B representing a double stranded restriction enzyme recognition site or a random nucleic acid sequence; A′ representing a nucleic acid sequence motif of 10 to 30 bp being complementary to the nucleic acid sequence motif of A; and R-prim representing a nucleic acid sequence complementary to a target sequence in a nucleic acid sequence to be amplified.

公开(公告)号：US11072829B2

公开(公告)日：2021-07-27

申请号：US16555683

申请日：2019-08-29

Applicant: AGILENT TECHNOLOGIES, INC.

Inventor： Dirk Goossens ,  Joachim De Schrijver ,  Jurgen Del Favero

IPC: C12Q1/68 ,  C12Q1/6883 ,  C12Q1/6809

Abstract: The present invention relates to the technical field of organ and tissue transplantation and specifically to methods allowing rejection of transplanted organs and tissues by a transplant patient. The present invention provides methods for non-invasive and ex vivo or in vitro detection of the presence or absence of transplant rejection, i.e. transplant health or rejection. The present methods allow for effective and continuous monitoring of transplant status with a minimal or absent discomfort for a transplant patent.